Podcast - NICE News – May 2026 cover art

Podcast - NICE News – May 2026

Podcast - NICE News – May 2026

Listen for free

View show details
The video version of this podcast can be found here: · https://youtu.be/hx1KVBpBbB4This episode makes reference to guidelines produced by the "National Institute for Health and Care Excellence" in the UK, also referred to as "NICE". The content on this channel reflects my professional interpretation/summary of the guidance and I am in no way affiliated with, employed by or funded/sponsored by NICE.NICE stands for "National Institute for Health and Care Excellence" and is an independent organization within the UK healthcare system that produces evidence-based guidelines and recommendations to help healthcare professionals deliver the best possible care to patients, particularly within the NHS (National Health Service) by assessing new health technologies and treatments and determining their cost-effectiveness; essentially guiding best practices for patient care across the country.My name is Fernando Florido and I am a General Practitioner in the United Kingdom. In this episode I go through new and updated recommendations published in May 2026 by the National Institute for Health and Care Excellence (NICE), focusing on those that are relevant to Primary Care only. I am not giving medical advice; this video is intended for health care professionals, it is only my summary and my interpretation of the guidelines and you must use your clinical judgement. Disclaimer:The Video Content on this channel is for educational purposes and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read or seen on this YouTube channel. The statements made throughout this video are not to be used or relied on to diagnose, treat, cure or prevent health conditions. In addition, transmission of this Content is not intended to create, and receipt by you does not constitute, a physician-patient relationship with Dr Fernando Florido, his employees, agents, independent contractors, or anyone acting on behalf of Dr Fernando Florido. Intro / outro music: Track: Halfway Through — Broke In Summer [Audio Library Release] Music provided by Audio Library Plus Watch: https://youtu.be/aBGk6aJM3IU Free Download / Stream: https://alplus.io/halfway-through There is a podcast version of this and other videos that you can access here: Primary Care guidelines podcast: · Redcircle: https://redcircle.com/shows/primary-care-guidelines· Spotify: https://open.spotify.com/show/5BmqS0Ol16oQ7Kr1WYzupK· Apple podcasts: https://podcasts.apple.com/gb/podcast/primary-care-guidelines/id1608821148 There is a YouTube version of this and other videos that you can access here: The Practical GP YouTube Channel: https://youtube.com/@practicalgp?si=ecJGF5QCuMLQ6hrk The Full NICE News bulletin for May 2026 can be found here: · https://www.nice.org.uk/guidance/published?from=2026-05-01&to=2026-05-31&ndt=Guidance&ndt=Quality+standardThe new Technology appraisal guidance [TA1152] Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity can be found here:· https://www.nice.org.uk/guidance/ta1152 TranscriptIf you are listening to this podcast on YouTube, for a better experience, switch to the video version. The link is in the episode description.Hello and welcome! I’m Fernando, a GP in the UK. In today’s episode, we’ll look at the NICE updates published in May 2026, focusing on what is relevant in Primary Care only. This month, we only have one technology appraisal that is relevant to primary care, which is semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity.Right, let’s jump into it.This particular technology appraisal recommends semaglutide for reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity.The difference is that this is not a general obesity recommendation.This is about secondary prevention in people who already have established cardiovascular disease and a BMI of at least 27.NICE defines established cardiovascular disease in this guidance as having at least one of the following: a previous MI, previous ischaemic or haemorrhagic stroke, or symptomatic peripheral arterial disease.For peripheral arterial disease, NICE specifies intermittent claudication with an ankle brachial index below 0.85 at rest, or previous peripheral arterial revascularisation, or amputation because of atherosclerotic disease.The recommendation is that semaglutide, up to a maintenance dose of 2.4 mg once weekly, can be used alongside standard routine management in order ...
adbl_web_anon_alc_button_suppression_t1
No reviews yet